General AML

Andrew Wei | EHA 2018 | Targeting apoptosis in AML


At the 23rd Congress of the European Hematology Association, Andrew Wei (chair of our Rest of the World steering committee) from Monash University, Melbourne, AU, discusses BCL2 inhibition which has become a promising therapeutic target in acute myeloid leukemia (AML). He further discussed an investigator-initiated phase Ib dose escalation study of venetoclax in combination with intensive chemotherapy in fit elderly AML patients.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF